

Edgar Filing: PHARMANETICS INC - Form 3

PHARMANETICS INC
Form 3
May 11, 2001

OMB APPROVAL

OMB Number
Expires:
Estimated average burden
hours per response 0.5

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*

(Last) (First) (Middle)
Bayer Corporation

(Street)
100 Bayer Road

(City) (State) (Zip)
Pittsburgh PA 15205-9741

2. Date of Event Requiring Statement (Month/Day/Year)

May 1, 2001

3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)

4. Issuer Name and Ticker or Trading Symbol

Pharmanetics, Inc. PHAR

5. Relationship of Reporting Person to Issuer
(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Edgar Filing: PHARMANETICS INC - Form 3

6. If Amendment, Date of Original (Month/Day/Year)

7. Individual or Joint/Group Filing (Check applicable line)

Form Filed by One Reporting Person

Form Filed by More than One Reporting Person

Table I -- Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature (Instr.)
Common Stock	2,050,000	D	
Series A Convertible Preferred Stock	0		

* If the Form is filed by more than one Reporting Person, see Instruction 5(b)(v).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Over)

Edgar Filing: PHARMANETICS INC - Form 3

FORM 3 (continued)

Table II -- Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security
	Date Exercisable	Expiration Date	Title	
Warrants			Common Stock 0	

Explanation of Responses:

Bayer Corporation

By: /s/ Kenneth F. Wobbekind

May 11, 2001

**Signature of Reporting Person

Date

Kenneth F. Wobbekind
Vice President, Assistant General Counsel
& Assistant Secretary

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

Edgar Filing: PHARMANETICS INC - Form 3

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.

Page 2